284 related articles for article (PubMed ID: 23699600)
1. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.
Kaiser MF; Johnson DC; Wu P; Walker BA; Brioli A; Mirabella F; Wardell CP; Melchor L; Davies FE; Morgan GJ
Blood; 2013 Jul; 122(2):219-26. PubMed ID: 23699600
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
5. Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Moreaux J; Rème T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
Mol Cancer Ther; 2012 Dec; 11(12):2685-92. PubMed ID: 23087257
[TBL] [Abstract][Full Text] [Related]
6. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of the MIR34B/C in multiple myeloma.
Wong KY; Yim RL; So CC; Jin DY; Liang R; Chim CS
Blood; 2011 Nov; 118(22):5901-4. PubMed ID: 21976676
[TBL] [Abstract][Full Text] [Related]
8. Methylation status of nine tumor suppressor genes in multiple myeloma.
Braggio E; Maiolino A; Gouveia ME; Magalhães R; Souto Filho JT; Garnica M; Nucci M; Renault IZ
Int J Hematol; 2010 Jan; 91(1):87-96. PubMed ID: 20037750
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of LPP/miR-28 in multiple myeloma.
Li Z; Wong KY; Chan GC; Chim CS
J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176
[TBL] [Abstract][Full Text] [Related]
10. Aberrant promoter methylation of SPARC in ovarian cancer.
Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
[TBL] [Abstract][Full Text] [Related]
11. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
[TBL] [Abstract][Full Text] [Related]
13. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma.
He Y; Wang Y; Li P; Zhu S; Wang J; Zhang S
Dig Dis Sci; 2011 Mar; 56(3):681-8. PubMed ID: 20725785
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation profiles of lymphoid and hematopoietic malignancies.
Takahashi T; Shivapurkar N; Reddy J; Shigematsu H; Miyajima K; Suzuki M; Toyooka S; Zöchbauer-Müller S; Drach J; Parikh G; Zheng Y; Feng Z; Kroft SH; Timmons C; McKenna RW; Gazdar AF
Clin Cancer Res; 2004 May; 10(9):2928-35. PubMed ID: 15131027
[TBL] [Abstract][Full Text] [Related]
15. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S; Brini AT; Vaiyapuri S; Alholle A; Dallol A; Arrigoni E; Kishida T; Hiruma T; Avigad S; Grimer R; Maher ER; Latif F
Epigenetics; 2013 Sep; 8(9):893-8. PubMed ID: 23887284
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.
Chim CS; Liang R; Fung TK; Choi CL; Kwong YL
J Clin Pathol; 2007 Jun; 60(6):664-9. PubMed ID: 17557868
[TBL] [Abstract][Full Text] [Related]
17. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.
Yu J; Zhang H; Gu J; Lin S; Li J; Lu W; Wang Y; Zhu J
BMC Cancer; 2004 Sep; 4():65. PubMed ID: 15367334
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.
Li Z; Wong KY; Calin GA; Chng WJ; Chan GC; Chim CS
Clin Epigenetics; 2019 May; 11(1):71. PubMed ID: 31064412
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers.
Youssef EM; Chen XQ; Higuchi E; Kondo Y; Garcia-Manero G; Lotan R; Issa JP
Cancer Res; 2004 Apr; 64(7):2411-7. PubMed ID: 15059893
[TBL] [Abstract][Full Text] [Related]
20. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
Wilop S; van Gemmeren TB; Lentjes MH; van Engeland M; Herman JG; Brümmendorf TH; Jost E; Galm O
Epigenetics; 2011 Aug; 6(8):1047-52. PubMed ID: 21934357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
